价格

Eisai GmbH

Edmund-Rumpler-Str. 3, Frankfurt Am Main, Hessen, 德国

概览

试验阶段分布

阶段

试验数

占比

4 期

16.7%

试验状态分布

进行中（未招募）

16.7%

已完成

66.7%

终止

16.7%

药物批准

按机构分类的批准

EMA

European Medicines Agency

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

药物批准

近期批准

LENVIMA 4 MG CAPSULAS DURAS

CIMA_AEMPS

2026-07-07

LEQEMBI 100 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION

FYCOMPA 4 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

CIMA_AEMPS

2022-01-21

FYCOMPA 6 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

CIMA_AEMPS

2022-01-21

FYCOMPA 2 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

CIMA_AEMPS

2022-01-21

ZONEGRAN 100 mg CAPSULAS DURAS

CIMA_AEMPS

2020-05-08

ZONEGRAN 100 MG CAPSULAS DURAS

CIMA_AEMPS

2020-03-04

资讯

暂无资讯文章

返回机构列表

Eisai GmbH

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（6）

A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy

Incidence and Resolution of Eribulin-induced peripheral Neuropathy (IRENE)

ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions

Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization

Randomized trial to assess efficacy and safety of an add-on treatment with zonisamide in adults with focal epileptic seizures with or without secondary generalizatio

药物批准

按机构分类的批准

近期批准

资讯